Prediction of CCND1 amplification using plasma DNA as a prognostic marker in oesophageal squamous cell carcinoma

[1]  J. Inazawa,et al.  Overexpression of SMYD2 relates to tumor cell proliferation and malignant outcome of esophageal squamous cell carcinoma. , 2009, Carcinogenesis.

[2]  K. Pantel,et al.  Cell-free Tumor DNA in Blood Plasma As a Marker for Circulating Tumor Cells in Prostate Cancer , 2009, Clinical Cancer Research.

[3]  José H. Fregnani,et al.  Evaluation of gene amplification and protein expression of HER-2/neu in esophageal squamous cell carcinoma using Fluorescence in situ Hybridization (FISH) and immunohistochemistry , 2009, BMC Cancer.

[4]  K. Chayama,et al.  Genetic polymorphisms and esophageal cancer risk , 2007, International journal of cancer.

[5]  U. Ghoshal,et al.  Influence of apoptosis (BCL2, FAS), Cell cycle (CCND1) and growth factor (EGF, EGFR) genetic polymorphisms on survival outcome: An exploratory study in squamous cell esophageal cancer , 2007, Cancer biology & therapy.

[6]  D. Ichikawa,et al.  Quantification of plasma cell-free DNA in patients with gastric cancer. , 2007, Anticancer research.

[7]  D. Ichikawa,et al.  Quantification of circulating plasma DNA fragments as tumor markers in patients with esophageal cancer. , 2007, Anticancer research.

[8]  Nobuyuki Tani,et al.  Circulating cell-free mRNA in plasma as a tumor marker for patients with primary and recurrent gastric cancer. , 2007, Anticancer research.

[9]  K. Nishio,et al.  Detection of Epidermal Growth Factor Receptor Mutations in Serum as a Predictor of the Response to Gefitinib in Patients with Non–Small-Cell Lung Cancer , 2006, Clinical Cancer Research.

[10]  A. V. Starikov,et al.  Cell-free and cell-bound circulating DNA in breast tumours: DNA quantification and analysis of tumour-related gene methylation , 2006, British Journal of Cancer.

[11]  M. Ohira,et al.  Prediction of MYCN amplification in neuroblastoma using serum DNA and real-time quantitative polymerase chain reaction. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[12]  D. Ichikawa,et al.  Comparison of methylation‐specific polymerase chain reaction (MSP) with reverse transcriptase‐polymerase chain reaction (RT‐PCR) in peripheral blood of gastric cancer patients , 2004, Journal of surgical oncology.

[13]  D. Ichikawa,et al.  Detection of aberrant methylation as a tumor marker in serum of patients with gastric cancer. , 2004, Anticancer research.

[14]  U. Pastorino,et al.  Quantification of free circulating DNA as a diagnostic marker in lung cancer. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[15]  P. Johnson,et al.  Plasma nucleic acids in the diagnosis and management of malignant disease. , 2002, Clinical chemistry.

[16]  J. Inazawa,et al.  Identification of cIAP1 as a candidate target gene within an amplicon at 11q22 in esophageal squamous cell carcinomas. , 2001, Cancer research.

[17]  A. Lam,et al.  Molecular biology of esophageal squamous cell carcinoma. , 2000, Critical reviews in oncology/hematology.

[18]  D. Beer,et al.  Detection of erbB-2 amplifications in tumors and sera from esophageal carcinoma patients. , 1999, Clinical cancer research : an official journal of the American Association for Cancer Research.

[19]  D. Carter.  TNM Classification of Malignant Tumors , 1998 .

[20]  P. Hainaut,et al.  Up-regulation of Fas (APO-1/CD95) ligand and down-regulation of Fas expression in human esophageal cancer. , 1998, Cancer research.

[21]  M. Kitajima,et al.  Cyclin D1 amplification as a new predictive classification for squamous cell carcinoma of the esophagus, adding gene information. , 1996, Clinical cancer research : an official journal of the American Association for Cancer Research.

[22]  D. Birnbaum,et al.  Oesophageal cancer and amplification of the human cyclin D gene CCND1/PRAD1. , 1995, British Journal of Cancer.

[23]  I. Weinstein,et al.  Amplification and expression of the human cyclin D gene in esophageal cancer. , 1992, Cancer research.

[24]  R Montesano,et al.  Frequent mutation of the p53 gene in human esophageal cancer. , 1990, Proceedings of the National Academy of Sciences of the United States of America.

[25]  I. Weinstein,et al.  Amplification of the EGF receptor and c‐myc genes in human esophageal cancers , 1988, International journal of cancer.

[26]  D. Park,et al.  MYC quantitation in cell-free plasma DNA by real-time PCR for gastric cancer diagnosis , 2009, Clinical chemistry and laboratory medicine.

[27]  S. Goodman,et al.  Circulating mutant DNA to assess tumor dynamics , 2008, Nature Medicine.

[28]  Peter D Siersema,et al.  Esophageal cancer. , 2008, Gastroenterology clinics of North America.

[29]  M. Fleischhacker,et al.  Circulating nucleic acids (CNAs) and cancer--a survey. , 2007, Biochimica et biophysica acta.

[30]  京本 良一.  Cyclin-D1-gene amplification is a more potent prognostic factor than its protein over-expression in human head-and-neck squamous-cell carcinoma , 1999 .

[31]  L. Sobin,et al.  TNM Classification of Malignant Tumours , 1987, UICC International Union Against Cancer.